Observe Medical Annual Report for 2021
Oslo, 29 April 2022 – Observe Medical ASA ("the Company" or "Observe Medical") today announces that the Company has published its Annual Report for 2021, which was approved by the board of directors on 28 April 2022.
"It has been a transformational start to 2022, so I would like to take this opportunity to focus on the way forward. We have a strong portfolio of proprietary medtech products available globally, an international and dedicated team, and the drive to succeed. We have an exciting road ahead, and I look forward to embarking on this journey alongside our dedicated and highly valued team,” commented Rune Nystad, CEO of Observe Medical.
The Annual Report for 2021 is attached to this notice and is available on the company’s website, www.observemedical.com, under Investor Relations.
For further information, please contact:
Rune Nystad, CEO Observe Medical
Mobile: +47 916 24 683
E-mail: rune.nystad@observemedical.com
Per Arne Nygård, CFO of Observe Medical
Mobile: +47 411 04 345
E-mail: perarne.nygard@observemedical.com
About Observe Medical
Observe Medical is a Nordic medtech company that develops, markets and sells innovative medtech products for the global market. The Company is committed to improving patient welfare and patient outcomes, improving clinical data accuracy and promoting positive health economics.
The Company seeks to drive growth by leveraging its expertise in sales and commercialization of its broad portfolio of medical technology products, mainly in urine measurement, anesthesiology/ICUs, surgery and wound care, in combination with targeted M&A.
The Company is headquartered in Oslo, Norway, with additional offices in Narvik, Norway and Gothenburg, Sweden, and subsidiaries in Finland and the US. In addition, Observe Medical has a direct sale organization in the Nordics and a distributor network internationally.
Further information is available at www.observemedical.com.